<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04954937</url>
  </required_header>
  <id_info>
    <org_study_id>21AS0001</org_study_id>
    <nct_id>NCT04954937</nct_id>
  </id_info>
  <brief_title>Convalescent Plasma Donor Vaccine Study An Observational Antibody Level Study.</brief_title>
  <acronym>C-VELVET</acronym>
  <official_title>Convalescent Plasma Donor Vaccine Study: An Observational Antibody Level Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NHS Blood and Transplant</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NHS Blood and Transplant</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a need to understand antibody responses following SARS-COV-2 infection and&#xD;
      subsequent vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational study to determine changes in antibody levels in individuals who&#xD;
      have previously donated COVID-19 convalescent plasma (CCP) and have now received at least one&#xD;
      dose of a COVID-19 vaccine. At present these donors could no longer donate CCP as their&#xD;
      virus-neutralising antibody levels do not reach the level required (Euroimmun of at least 6&#xD;
      IgG signal/control cutoff).&#xD;
&#xD;
      Two blood samples (9 ml total) will be collected at a local NHSBT donor centre to test the&#xD;
      levels of the virus-neutralising antibodies in the plasma against different viral strains.&#xD;
&#xD;
      The results of this study will:&#xD;
&#xD;
        1. Determine whether NHSBT will collect CCP or plasma for medicines (PFM) from vaccinated&#xD;
           members of the public that could have boosted antibody levels following vaccine&#xD;
           administration.&#xD;
&#xD;
        2. Understand if antibody levels rebound to a concentration suitable for CCP and PFM.&#xD;
&#xD;
        3. Provide the evidence to support the use of CCP for the early treatment in COVID&#xD;
           (currently under consideration as a collaboration with European partners).&#xD;
&#xD;
        4. Assist in development of recording vaccination status on NHSBT databases of donors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">April 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in antibody levels post-vaccination assessed via Euroimmun assay</measure>
    <time_frame>at least 28 days following vaccination</time_frame>
    <description>Euroimmun assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase in antibody levels post-vaccination assessed via Roche IgG assay</measure>
    <time_frame>at least 28 days following vaccination</time_frame>
    <description>Roche IgG assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase in antibody levels post-vaccination assessed vial live virus neutralization</measure>
    <time_frame>at least 28 days following vaccination</time_frame>
    <description>Live virus neutralization (SARS-CoV-2 wild type (WT), alpha,beta and delta variants)</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Two EDTA samples will be collected from each donor. First sample will be analysed for&#xD;
      SARS-CoV-2 IgG antibodies using EUROimmun assay. A second sample will be analysed for&#xD;
      SARS-CoV-2 neutralising antibody testing and ELISA or other immunological assays for anti-S&#xD;
      antibodies using SARS-CoV-2 strains.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals who have had a previous SARS-CoV-2 infection&#xD;
&#xD;
          -  Individuals who have previously donated COVID-19 convalescent plasma (CCP)&#xD;
&#xD;
          -  Received at least one dose of a SARS-CoV-2 vaccine (any type of vaccine)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not received a SARS-CoV-2 vaccine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lise Estcourt, MB BChir, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>NHS Blood and Transplant</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise Estcourt, MB BChir, DPhil</last_name>
    <phone>07823 351936</phone>
    <email>lise.estcourt@nhsbt.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Mora, PhD</last_name>
    <phone>00 44 7889304288</phone>
    <email>ana.mora@nhsbt.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NHSBT - Birmingham Donation Centre</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Brain</last_name>
      <email>Richard.brain@nhsbt.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NHS Blood and Transplant</investigator_affiliation>
    <investigator_full_name>Lise Jane Estcourt</investigator_full_name>
    <investigator_title>Haematologist Consultant</investigator_title>
  </responsible_party>
  <keyword>Anti-SARS-CoV-2 antibodies</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Convalescent plasma</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>N/A- Individual participant data will note be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

